Expanded room configurations, nature-inspired interiors, and new dining concepts by Graphic Holdings enhance the guest experience across two neighboring properties TOKYO, March 2, 2026 /PRNewswire/ -- Mitsui Fudosan Co., Ltd. and Mitsui Fudosan Hotel Management Co., Ltd. today announced the reop...
Expanded room configurations, nature-inspired interiors, and new dining concepts by Graphic Holdings enhance the guest experience across two neighboring properties TOKYO, March 2, 2026 /PRNewswire/ -- Mitsui Fudosan Co., Ltd. and Mitsui Fudosan Hotel Management Co., Ltd. today announced the reop...
SINGAPORE, March 2, 2026 /PRNewswire/ -- Digital travel platform, Agoda released insights into Thailand's popular Valentine's Day destinations, based on accommodation search trends among Thai travelers traveling as couples. This year, searches for Surat Thani grew the fastest, with more than...
SINGAPORE, March 2, 2026 /PRNewswire/ -- Digital travel platform, Agoda released insights into Thailand's popular Valentine's Day destinations, based on accommodation search trends among Thai travelers traveling as couples. This year, searches for Surat Thani grew the fastest, with more than...
BEIJING, March 2, 2026 /PRNewswire/ -- A report from People's Daily: The upcoming "two sessions," the annual meetings of China's top legislature, the National People's Congress (NPC), and the top political advisory body, the National Committee of the Chinese People's Political Consultative Conference (CPPCC),...
BEIJING, March 2, 2026 /PRNewswire/ -- A report from People's Daily: The upcoming "two sessions," the annual meetings of China's top legislature, the National People's Congress (NPC), and the top political advisory body, the National Committee of the Chinese People's Political Consultative Conference (CPPCC),...
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell ...
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell ...
New platform reinforces Infobip's shift to AI-first customer experience in its 20th year KUALA LUMPUR, Malaysia, March 2, 2026 /PRNewswire/ -- Global AI-first cloud communications platform Infobip, which celebrates its 20th anniversary this year, is set to launch its AI-native fully managed solution AgentOS. The ...
New platform reinforces Infobip's shift to AI-first customer experience in its 20th year KUALA LUMPUR, Malaysia, March 2, 2026 /PRNewswire/ -- Global AI-first cloud communications platform Infobip, which celebrates its 20th anniversary this year, is set to launch its AI-native fully managed solution AgentOS. The ...